Muscle spasms and stiffness, known as muscle spasticity, are common symptoms of various neurological disorders and injuries to the central nervous system like cerebral palsy, multiple sclerosis, spinal cord injuries, and stroke. Drugs used to manage muscle spasticity aim to reduce contraction in overactive muscles and regain flexibility. Oral medications like baclofen and dantrolene are often prescribed, but alternatives like botox injections directly into affected muscles are also used.
The global Muscle Spasticity Market is estimated to be valued at US$ 4942.44 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the muscle spasticity market is the increasing demand for non-oral drugs and minimally invasive treatments. While oral medications form the mainstay of initial treatment, their long term use can cause side effects like drowsiness, dizziness, and weakness. This has driven research into alternative neuromodulation techniques like localized injections of botox or phenol into hypertonic muscles instead of systemic drugs. Technologies promoting selective nerve blocking through implants are also gaining interest for conditions requiring long term management. Such localized non-oral therapies help avoid systemic side effects and offer better symptom control through targeted muscle relaxation.
Porter’s Analysis
Threat of new entrants: Low barriers to entry due to availability of generic drugs; however, presence of large established players makes it difficult for new players.
Bargaining power of buyers: Large customer base with increasing awareness; however, buyers have less influence due to lack of substitutes.
Bargaining power of suppliers: Suppliers have moderate to high bargaining power due to intellectual property patents held by few innovator companies.
Threat of new substitutes: Limited threat due to lack of alternative treatment options for muscle spasticity.
Competitive rivalry: High due to presence of many generic and branded product manufacturers globally.
Key Takeaways
The Global Muscle Spasticity Market Size is estimated to be valued at US$ 4942.44 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030.
The global Muscle Spasticity market is expected to witness high growth over the forecast period. Europe is currently the largest market for muscle spasticity drugs due to higher disease prevalence and government support for research. North America also captures a significant share and is expected to grow at a steady pace through 2030. Asia Pacific is the fastest growing region driven by unmet medical needs, rising income level, and expansion of key players in developing countries.
Key players – Key players operating in the muscle spasticity market are Blackmores Limited, Vitaco Holdings Limited, Integria Healthcare, Bioglan, Deep Blue Health (NZ) Co. Limited, Phytomed, NZ Herbals, and Sanderson. These players are focusing on strategic collaborations and new product launches to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it